Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m

Strides Pharma Science and Orbicular Pharmaceutical Technologies Private Limited (Orbicular) today informed that they have entered into a strategic partnership to develop, manufacture and commercialize nasal sprays for the global markets.

Orbicular, a speciality pharmaceutical company focused on research and product development, will use its expertise in drug delivery and formulation to develop nasal sprays for global markets. The Company has deployed a thorough product design approach to ensure the nasal sprays are robust, following "Quality-by-Design" principles. Orbicular has a stellar product development and licensing track record across various Complex Injectables, Topicals, Ophthalmic, Parenteral, Nasal Spray, and Inhalation product assets.

Strides will commercialize these nasal sprays across the markets using its commercial engine in the US, Europe, and several other markets. The products will be manufactured at Company's state-of-the-art Chestnut Ridge, New York facility. The facility has comprehensive capabilities for nasal spray manufacturing in the unit dose and multi-dose format, including for controlled substances. The site has been in continuous operation for four decades with approval from USFDA and Drug Enforcement Administration (DEA) with a strong compliance track record. Strides acquired this facility in October 2021 from Endo Inc.

The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m.